Search results

1

Drug-induced diseases in otolaryngology – causes, clinical signs, treatment

100%

Woroń J., Jurkiewicz D., Rapiejko P., Lorkowska- Zawicka B., Tymiński R., Wordliczek J.

Polish Journal of Otolaryngology

|

2021

|

vol. 75

|

issue 5

9-15

EN

Introduction: In the daily practice of an otolaryngologist, we encounter cases where the symptoms are not the result of disease but result from pharmacotherapy. In the case of symptoms such as hearing loss, tinnitus, or dizziness, polytherapy may be used as the basis for their occurrence, which, due to the lack of rationality in combining drugs, leads to symptoms that the patient and the doctor very often interpret as a new disease syndrome. Aim: The aim of the study is to show and to raise awareness of the fact that the symptoms of hearing organ impairment are frequently drug-related and only a modification of the currently used pharmacotherapy is a rational procedure in such cases. Material: This paper describes 30 cases who developed side effects of polypharmacy in the form of hearing disorders, dizziness, and tinnitus. The causes of drug-related complications were discussed, as well as effective methods of their prevention.

2

Safety of oral nifuroxazide – analysis of data from a spontaneous reporting system

88%

Karlowicz-Bodalska K., Głowacka K., Boszkiewicz K., Han S., Wiela-Hojeńska A.

Acta Poloniae Pharmaceutica - Drug Research

|

2019

|

vol. 76

|

issue 4

745-751

EN

Nifuroxazide is a popular chemotherapeutic agent, that is widely used in Poland in acute and chronic bacterial diarrhea treatment. It is available in pharmacies as over-the-counter tablets for adults and a suspension on prescription for children. The aim of the study was to assess the safety of nifuroxazide therapy. Adverse reaction reports from the Regional Pharmacovigilance Center in Wroclaw, the pharmaceutical company PPF Hasco-Lek, and VigiAccess and EudraVigilance databases were analyzed. Based on the analysis of the data collected from the above sources, nifuroxazide have shown a high therapeutic value in the gastrointestinal tract infections, maintaining high safety of usage at the same time. The number of drug application adverse reactions in Poland is not so high primarily due to high safety profile and low patient awareness of the possibility of reporting drug side effects.

3

Synergistic interaction of levetiracetam with gabapentin in the mouse 6 Hz psychomotor seizure model – a type II isobolographic analysis

75%

Wlaz A., Kondrat-Wrobel M. W., Zaluska K., Kochman E., Rekas A. R., Luszczki J. J.

Current Issues in Pharmacy and Medical Sciences

|

2015

|

vol. 28

|

issue 3

204-207

EN

This study was aimed at characterizing the anticonvulsant effects of levetiracetam in combination with gabapentin, in the mouse 6 Hz psychomotor seizure model. Herein, psychomotor seizures were evoked in male albino Swiss mice by a current (32 mA, 6 Hz, 3 s stimulus duration) delivered via ocular electrodes. Type II isobolographic analysis was used to characterize the anticonvulsant interactions between the drugs in combination, for fixed-ratios of 1:1, 1:2, 1:5 and 1:10. The type II isobolographic analysis revealed that the combinations of levetiracetam with gabapentin for the fixed-ratios of 1:5 and 1:10 were supra-additive (synergistic; P<0.05) in terms of seizure suppression, while the combinations for the fixed-ratios of 1:1 and 1:2 were additive in the mouse 6 Hz psychomotor seizure model. We conclude that, as the combinations of levetiracetam with gabapentin for the fixed-ratios of 1:5 and 1:10 exerted supra-additive (synergistic) interaction in the mouse 6 Hz psychomotor seizure model, this may be considered as particularly favorable combinations in further clinical practice.

4

Pharmacotherapy of pain in cancer patients – recommendations of the Polish Association for the Study of Pain, Polish Society of Palliative Medicine, Polish Society of Oncology, Polish Society of Family Medicine, Polish Society of Anaesthesiology and Intensive Therapy and Association of Polish Surgeons

63%

Wordliczek J., Kotlińska-Lemieszek A., Leppert W., Woroń J., Dobrogowski J., Krajnik M., Przeklasa-Muszyńska A., Jassem J., Drobnik J., Wrzosek A., Janecki M., Pyszkowska J., Kocot-Kępska M., Zajączkowska R., Filipczak-Bryniarska I., Boczar K., Jakowicka-Wordliczek J., Malec-Milewska M., Kübler A., Suchorzewski M., Mordarski S., Dziki A., Paśnik K.

Polish Journal of Surgery

|

2018

|

vol. 90(4)

55-84

EN

Guidelines for the pharmacotherapy of pain in cancer patients were developed by a group of 21 experts of the Polish Association for the Study of Pain, Polish Society of Palliative Medicine, Polish Society of Oncology, Polish Society of Family Medicine, Polish Society of Anaesthesiology and Intensive Therapy and Association of Polish Surgeons. During a series of meetings, the experts carried out an overview of the available literature on the treatment of pain in cancer patients, paying particular attention to systematic reviews and more recent randomized studies not included in the reviews. The search was performed in the EMBASE, MEDLINE, and Cochrane Central Register of Controlled Trials databases using such keywords as “pain”, “cancer”, “pharmacotherapy”, “analgesics”, and similar. The overviewed articles included studies of pathomechanisms of pain in cancer patients, methods for the assessment of pain in cancer patients, and drugs used in the pharmacotherapy of pain in cancer patients, including non-opioid analgesics (paracetamol, metamizole, non-steroidal anti-inflammatory drugs), opioids (strong and weak), coanalgesics (glucocorticosteroids, α2-adrenergic receptor agonists, NMDA receptor antagonists, antidepressants, anticonvulsants, topical medications) as well as drugs used to reduce the adverse effects of the analgesic treatment and symptoms other than pain in patients subjected to opioid treatment. The principles of opioid rotation and the management of patients with opioidophobia were discussed and recommendations for the management of opioid-induced hyperalgesia were presented. Drugs used in different types of pain experienced by cancer patients, including neuropathic pain, visceral pain, bone pain, and breakthrough pain, were included in the overview. Most common interactions of drugs used in the pharmacotherapy of pain in cancer patients as well as the principles for the management of crisis situations. In the final part of the recommendations, the issues of pain and care in dying patients are discussed. Recommendations are addressed to physicians of different specialties involved in the diagnostics and treatment of cancer in their daily practice. It is the hope of the experts who took part in the development of these recommendations that the recommendations would become helpful in everyday medical practice and thus contribute to the improvement in the quality of care and the efficacy of pain treatment in this group of patients.

Refine search results

Drug-induced diseases in otolaryngology – causes, clinical signs, treatment

Safety of oral nifuroxazide – analysis of data from a spontaneous reporting system

Synergistic interaction of levetiracetam with gabapentin in the mouse 6 Hz psychomotor seizure model – a type II isobolographic analysis